Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer

Jae Hee Ahn; Sun Young Kim; Ye Ji Kim; Suk Young Lee; Jae Hyoung Lee; Seung Hun Kang; Ho Cheol Hong; Sae Jeong Yang; Hye Jin Yoo; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Kyung Mook Choi; Sei Hyun Baik; Dong Seop Choi; Hae Yoon Choi

doi:10.3803/EnM.2011.26.4.345

Journal List > Endocrinol Metab > v.26(4) > 1085914

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ahn, Kim, Kim, Lee, Lee, Kang, Hong, Yang, Yoo, Seo, Kim, Kim, Choi, Baik, Choi, and Choi: Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following 131I Postablation Scan in Differentiated Thyroid Cancer

Case Report

Endocrinol Metab 2011;26(4):345-347.

Published online: 5 December 2011

DOI: https://doi.org/10.3803/EnM.2011.26.4.345

Hyperprolactinemia-Associated Breast Uptake of Radioiodine Following ¹³¹I Postablation Scan in Differentiated Thyroid Cancer

Jae Hee Ahn, Sun Young Kim, Ye Ji Kim, Suk Young Lee, Jae Hyoung Lee, Seung Hun Kang, Ho Cheol Hong¹, Sae Jeong Yang¹, Hye Jin Yoo¹, Ji A Seo², Sin Gon Kim, Nan Hee Kim², Kyung Mook Choi¹, Sei Hyun Baik¹, Dong Seop Choi, Hae Yoon Choi¹

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

²Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea

Corresponding author: Hae Yoon Choi Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 80 Guro 2-dong, Guro-gu, Seoul 152-703, Korea Tel: +82-2-2626-3046, Fax: +82-2-2626-1096, E-mail: kahlua99@hanmail.net

Received 9 June 2011 Accepted 11 July 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

초록

Scanning with whole-body¹³¹ I scintigraphy after surgery has been a valuable diagnostic modality in the surveillance of patients with differentiated thyroid cancer. Radioiodine uptake is rarely observed in non-lactating breast tissue, which mimics thyroid cancer me-tastasis. We now report a case of a 45-year-old female thyroid cancer patient who underwent radioiodine therapy, and in whom breast uptake of radioiodine was observed on a post-therapy whole body scan. Her serum prolactin level was elevated to 328 ng/mL at the time of the radioiodine uptake, and the hyperprolactinemia was induced by her antipsychotic medications. Six months after she discontinued that medication, her serum prolactin level was normalized to 12.6 ng/mL and breast uptake of iodine was no longer present in a follow-up whole body scan.

Keywords: Antipsychotic agents, Differentiated thyroid cancer, Hyperprolactinemia

REFERENCES

1. Baeumler GR, Joo KG. Radioactive iodine uptake by breasts. J Nucl Med. 27:149–151. 1986.

2. Kao PF, Chang HY, Tsai MF, Lin KJ, Tzen KY, Chang CN. Breast uptake of iodine-131 mimicking lung metastases in a thyroid cancer patient with a pituitary tumour. Br J Radiol. 74:378–381. 2001.

3. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, Durante C, Maranghi M, Filetti S, Russo D. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. Thyroid. 17:363–366. 2007.

4. Hammami MM, Bakheet S. Radioiodine breast uptake in nonbreastfeed-ing women: clinical and scintigraphic characteristics. J Nucl Med. 37:26–31. 1996.

5. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab. 83:2493–2496. 1998.

6. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 141:443–457. 1999.

7. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 24:48–77. 2003.

8. Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, Carrasco N. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 10:4294–4302. 2004.

9. Cho JY, Léveillé R, Kao R, Rousset B, Parlow AF, Burak WE Jr, Mazzaferri EL, Jhiang SM. Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab. 85:2936–2943. 2000.

10. Riesco-Eizaguirre G, Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol. 155:495–512. 2006.

11. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 13:797–826. 2006.

12. Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, Filetti S, Schlumberger M. Sodium iodide symporter expression and radioiodine dis-tribution in extrathyroidal tissues. J Endocrinol Invest. 27:1010–1014. 2004.

13. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics–a review. Hum Psychopharmacol. 25:281–297. 2010.

14. Bakheet SM, Hammami MM. Patterns of radioiodine uptake by the lac-tating breast. Eur J Nucl Med. 21:604–608. 1994.

15. Renier C, Yao C, Goris M, Ghosh M, Katznelson L, Nowles K, Gambhir SS, Wapnir I. Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol. 16:962–968. 2009.

Fig. 1.

Positron emission tomog-raphy-computed tomography performed 5 months after total thyroid-ectomy. There was no evidence of tu-mor recurrence or metastasis.

Fig. 2.

¹³¹ I whole body scan. A. ¹³¹ I whole body scan performed 72 hours after an radioiodine ablation (RIA) (150 mCi). There were multiple sites of iodine uptake in functioning thyroid tissue or regional lymph nodes in the thyroid area. Diffuse mild breast uptake was observed in scanned images. B. ¹³¹ I whole body scan performed 6 months after the RIA (150 mCi). There was no longer iodine uptake in either breast.

TOOLS

Similar articles